Omeprazole Raw Materials Powder

CAS:73590-58-6

MF:C17H19N3O3S

MW:345.42 

EINECS:615-996-8

Specification: 99% min Omeprazole Powder

Sample: Omeprazole Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Omeprazole Powder Usage and Synthesis.

Omeprazole is a kind of proton pump inhibitor that can effectively inhibit the secretion of gastric acid. The product names circulating on the market include ameprazole, omirazole, subflumidazole, losec, methoxysulfonazole, woprazole, and womiprazole, which belong to the class of acid suppressive drugs.

Other common acid suppressive drugs include Pantoprazole, Rabeprazole, and esomeprazole. The mechanism of action is to selectively act on the parietal cells of the gastric mucosa, inhibit the activity of H+,K+ -ATPase on the secretory microtubules formed by the apical membrane of the parietal cells of the gastric mucosa and the tubular vesicles in the cytoplasm, thus effectively inhibiting the secretion of gastric acid, with rapid effect, which is suitable for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis and gastrinoma (Zuo-Ai syndrome).

However, it should be noted that overuse of acid suppressive drugs such as omeprazole can lead to a decrease in the concentration of stomach acid and weaken the acidity, so that the bacteria entering the stomach may not be killed, and enter the intestine, doubling the risk of intestinal infection, and then diarrhea may be possible.

Due to the reduced stomach acid affect digestion, and then affect the intestinal absorption of calcium, iron and other trace elements and vitamins, resulting in calcium deficiency in the body, prone to fracture.

Uses and functions of  Omeprazole.

1. For gastric and duodenal ulcers, stress ulcers, etc.

2. For reflux oesophagitis, gastrinoma.

3. This injection can also be used for:

①Gastrointestinal bleeding, such as peptic ulcer bleeding, anastomotic ulcer bleeding, etc., as well as the prevention of upper gastrointestinal bleeding caused by severe diseases (such as cerebral haemorrhage, severe trauma, etc.) and after gastric surgery.

② Acute gastric mucosal injury complicated by stress or caused by non-steroidal anti-inflammatory drugs.

③ After general anaesthesia or major surgery and in comatose patients to prevent acid reflux and aspiration pneumonia.

4. Combined with amoxicillin and clarithromycin, or with metronidazole and clarithromycin, it can effectively kill Helicobacter pylori (Hp).

Omeprazole is a proton pump inhibitor with a strong and prolonged inhibitory effect on gastric acid secretion in animals and humans. It is clinically used in the treatment of peptic ulcer, reflux oesophagitis, Zollinger-Ellison syndrome, and eradication of Helicobacter pylori (HP) with satisfactory efficacy. It is suitable for peptic ulcer, reflux oesophagitis and so on.

Proton pump inhibitors, i.e. inhibitors of H+-K+-ATPase in the mural cells. It has a strong and long-lasting effect of inhibiting gastric acid secretion due to basal gastric acid and food, pentagastrin.

The effect is fast, reversible, and without H2 receptor antagonist-induced mental side effects.

Used for gastric and duodenal ulcers, reflux or erosive oesophagitis, Zo-Edward's syndrome, etc. It is also effective in gastric and duodenal ulcers that are not effective with H2 receptor antagonists.

Pharmacological Effects of Omeprazole.

Omeprazole is a proton pump inhibitor used in the treatment of peptic ulcer and gastroesophageal reflux disease (GERD), etc. It specifically acts on the site of the proton pump of the gastric mural cells and is converted to the active form of sulfenamide, which then irreversibly binds to the sulfhydryl group of the proton pump through a disulfide bond and generates a sulfenamide-proton pump (H+-K+-ATPase) It can inhibit the activity of this enzyme, so that the H+ in the wall cells can not be transported to the lumen of the stomach, and the final step of gastric acid secretion can be blocked, which can greatly reduce the amount of gastric acid in the gastric juice.

Therefore, it has a strong and long-lasting inhibitory effect on gastric acid secretion caused by a variety of reasons (e.g., basal gastric acid secretion as well as gastric acid secretion caused by histamine, pentagastrin, and stimulation of the vagus nerve, including gastric acid secretion caused by dibutyldicyclic adenosine acid, which can not be inhibited by H2-receptor blocking drugs). This is related to the irreversible nature of the inhibitory effect of the product on the proton pump, and the acid secretion can be restored only after the formation of a new proton pump.

Omeprazole was developed by AstraZeneca Pharmaceuticals of Sweden and first marketed in Sweden in 1988 under the trade name Losec, and by 1992 had been approved and used in 65 countries and regions, and was listed as the number one best-selling drug in the world for three consecutive years from 1998 to 2000, and its sales in 2002 were US$5.2 billion.

Production method of Omeprazole Powder.

3,5-Dimethyl-2-hydroxymethyl-4-methoxypyridine was chlorinated to produce 2-chloromethyl-3,5-dimethyl-4-methoxypyridine.4-Methoxy 1,2-phenylenediamine was reacted with potassium xanthate to produce 2-mercapto-5-methoxybenzimidazole, which in turn was reacted with the pyridine Chemicalbook pyridine derivative obtained above to produce 2-[(3,5-dimethyl-4- (3,5-dimethyl-4-pyridin-2-yl)methylthio]-5-methoxy-1H-benzimidazole, and finally oxidised with m-chloroperbenzoic acid in chloroform at 5°C to obtain omeprazole. The crude omeprazole can be recrystallised with acetonitrile.